WeightWatchers recently announced a $132 million deal to acquire telehealth company Sequence and enter the prescription drug space (think: GLP-1 drugs like Wegovy and Ozempic). It begs the question: why is a company built on personal accountability facilitating medical interventions? We ask our guest, WeightWatchers CEO Sima Sistani. Before and after the interview, Nayeema and Kara discuss their own experiences with diet fads and whether drugs like Wegovy and Ozempic will help America deal with the obesity epidemic or simply avoid tackling underlying issues like food supply, corporate greed and light regulation.

Questions? Comments? Email us at on@voxmedia.com or find us on Twitter @karaswisher and @nayeema 

Learn more about your ad choices. Visit podcastchoices.com/adchoices